Skip to content

Studying Special Immune Cells in the Blood of People with Breast Lumps.

Identification and quantification of circulating Myeloid derived suppressor cells (MDSCs) in breast lesions - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/05/087822
Enrollment
45
Registered
2025-05-28
Start date
Unknown
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D249- Benign neoplasm of unspecified breast Health Condition 2: C509- Malignant neoplasm of breast of unspecified site

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Maulana Azad Medical College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Newly diagnosed cases of benign and malignant breast lesions on FNAC/Tru-cut biopsy specimens.

Exclusion criteria

Exclusion criteria: Insufficient material on FNAC/Tru-cut biopsy.

Design outcomes

Primary

MeasureTime frame
Percentage of circulating Myeloid derived suppressor cells(MDSCs) in benign, malignant breast lesions and controls.Timepoint: Baseline

Secondary

MeasureTime frame
1.Association of circulating PMN-MDSCs, Mo-MDSCs and e-MDSCs in benign and malignant breast lesions with clinicopathological parameters like age, parity, size of the lump, overlying skin changes, nipple discharge, cervical and axillary lymph nodes, organomegaly and pathological parameters like type of benign lesion, TNM staging, histopathological grading, hormone status, number of lymph nodes involved and metastasis. 2.Difference in percentages of circulating MDSCs in malignant breast lesions, prechemotherapy/ presurgery and post-chemotherapy/post-surgery.Timepoint: Baseline

Countries

India

Contacts

Public ContactDr Prerna Arora

Maulana Azad Medical College

drprernaarora27@gmail.com9999952113

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026